Results 41 to 50 of about 3,132 (216)

Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD

Journal of VitreoRetinal Diseases
Purpose: To compare the rates of intraocular inflammation (IOI) in patients with neovascular age-related macular degeneration (nAMD) after injection of intravitreal (IVT) antivascular endothelial growth factor drugs.
Marta Stevanovic, Nicole Koulisis, Tom Chen, Stavros N. Moysidis, Bruce Burkemper, Brian C. Toy, Narsing A Rao, Dean Eliott, Mark S. Humayun   +8 more
semanticscholar   +1 more source

Real‐world incidence and clinical characteristics of intraocular inflammation following intravitreal faricimab therapy: A safety study

Acta Ophthalmologica, EarlyView.
Abstract Purpose To estimate the real‐world incidence of intraocular inflammation (IOI) following intravitreal faricimab injections at a large, highly specialized tertiary centre. Methods Single‐centre, retrospective cohort study with chart review using an electronic injection database and electronic medical records from November 2023 to August 2024 ...
Miklos Schneider, Leyla Turan, Farah Arif, Jakob Bjerager, Oliver Niels Klefter, Carsten Faber, Yousif Subhi, Javad Nouri Hajari   +7 more
wiley   +1 more source

One-year outcomes after switching to faricimab in eyes with pre-treated neovascular age-related macular degeneration: a Swiss Retina Research Network report.

Ophthalmology Retina
PURPOSE To report the efficacy and safety of switching to faricimab in a real-world, Swiss cohort of patients with pre-treated neovascular age-related macular degeneration (nAMD).
Gabriela Grimaldi, A. Ambresin, I. Pfister, Christin Schild, C. Plasencia, Katja Hatz, Richard Stillenmunkes, Marion R. Munk, Arianna Paris, M. Menghini, D. Artemiev, Andreas Ebneter, Jennifer Cattaneo, E. C. de Oliveira Figueiredo, C. Eandi, Jacqueline Fröhlich, N. Feltgen, T. Spitznagel, G. Somfai, Mariano Cozzi, S. Zweifel, A. Weinberger, Justus G. Garweg   +22 more
semanticscholar   +1 more source

Switching to faricimab from aflibercept during maintenance treatment period for age-related macular degeneration

Scientific Reports
To compare the short-term treatment outcomes of aflibercept and faricimab for neovascular age-related macular degeneration (nAMD) during the maintenance treatment period, we included 82 eyes of 74 patients who switched from aflibercept to faricimab ...
Misa Masaoka, Kenji Yamashiro
doaj   +1 more source

Efficacy of Initial Intravitreal Faricimab Injection after Switching from Aflibercept to Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration

Ophthalmic Research
Introduction: Previous studies have demonstrated the efficacy of faricimab where the intervention in treatment-resistant neovascular age-related macular degeneration (nAMD) had been switched from aflibercept to faricimab.
Yutao Du, Yasmine Sahraie, Meg Das, Andreas Katsimpris   +3 more
doaj   +1 more source

Faricimab in Neovascular AMD

, 2023
Abstract Purpose Assess short-term real-world outcomes in neovascular aged-related macular degeneration (nAMD) treated with novel faricimab. Methods Retrospective case series of nine patients with nAMD (11 eyes) treated with faricimab between May and November 2022.
Paulo Eduardo Stanga, Francisco Javier Valentin Bravo, Sebastian Stanga, Ursula Reinstein, Salvador Pastor Idoate, Susan Downes   +5 more
openaire   +1 more source

Faricimab Treat-and-Extend Dosing for Macular Edema due to Retinal Vein Occlusion: 72-Week Results From the BALATON and COMINO Trials.

Ophthalmology Retina
PURPOSE To assess the efficacy, durability, and safety of dual angiopoietin-2/vascular endothelial growth factor inhibition with faricimab dosed per a modified treat-and-extend (T&E)-based regimen in patients with retinal vein occlusion (RVO).
Carl J. Danzig, C. Dinah, F. Ghanchi, L.-O. Hattenbach, A. Khanani, T. Lai, Masahiko Shimura, Francis Abreu, Pablo Arrisi, Ying Liu, Liliana P. Paris, Anne-Cecile Retiere, Jeffrey R. Willis, P. Schlottmann   +13 more
semanticscholar   +1 more source

Neovascular glaucoma at a tertiary Centre in Finland, 2008–2024: A retrospective cohort study

Acta Ophthalmologica, EarlyView.
Abstract Purpose Neovascular glaucoma (NVG) is a refractory secondary glaucoma, yet longitudinal outcome data remain limited. This study reports its aetiologies, treatments and outcomes. Methods Patients with NVG were identified through electronic medical record review.
Gilbert Simons, Mikael von Fersen, Paula Summanen, Mika Harju   +3 more
wiley   +1 more source

Ocular Manifestations of Metabolic Syndrome: A Systemic Vascular Phenotype

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Context Metabolic syndrome (MetS) is defined by central obesity, insulin resistance, hypertension and dyslipidemia. MetS affects over one‐third of US adults. Beyond its cardiovascular burden, MetS has clinically relevant associations with ocular health and may contribute to a systemic vascular and neuro‐metabolic phenotype involving the retina,
Ron T. Varghese, Ansu A. John
wiley   +1 more source

Analysis of the aqueous humor before and after the administration of faricimab in patients with nAMD

Scientific Reports
This study aimed to evaluate the changes in cytokine levels in the aqueous humor and factors of treatment resistance following intravitreal faricimab injection in treatment-naïve patients with neovascular age-related macular degeneration.
Ryo Nonogaki, Hikaru Ota, Jun Takeuchi, Yuyako Nakano, Ai Fujita Sajiki, Takahito Todoroki, Koichi Nakamura, Hiroki Kaneko, Koji M. Nishiguchi   +8 more
doaj   +1 more source